Q2 2025 Holdings
Filed 2025-08-14 | 64 holdings | $5.9B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Ascendis Pharma A/S(ASND) | SH | 04351P101 | $1.8B | 10,281,496 | 29.9% |
| Vaxcyte Inc(PCVX) | SH | 92243G108 | $389.0M | 11,965,991 | 6.6% |
| Rhythm Pharmaceuticals Inc(RYTM) | SH | 76243J105 | $351.4M | 5,561,359 | 5.9% |
| Janux Therapeutics Inc(JANX) | SH | 47103J105 | $258.5M | 11,189,693 | 4.4% |
| Avidity Biosciences Inc(RNA) | SH | 05370A108 | $206.4M | 7,266,031 | 3.5% |
| Arcellx Inc(ACLX) | SH | 03940C100 | $200.0M | 3,036,527 | 3.4% |
| 89Bio Inc(ETNBGBP) | SH | 282559103 | $195.3M | 19,889,683 | 3.3% |
| ARS Pharmaceuticals Inc(SPRY) | SH | 82835W108 | $189.5M | 10,860,977 | 3.2% |
| Newamsterdam Pharma Co NV(NAMS) | SH | N62509109 | $183.6M | 10,138,938 | 3.1% |
| Sionna Therapeutics Inc(SION) | SH | 829401108 | $181.2M | 10,445,322 | 3.1% |
| Cidara Therapeutics Inc(CDTX) | SH | 171757206 | $163.9M | 3,365,523 | 2.8% |
| Edgewise Therapeutics Inc(EWTX) | SH | 28036F105 | $129.8M | 9,902,633 | 2.2% |
| Lenz Therapeutics Inc(LENZ) | SH | 52635N103 | $122.5M | 4,178,823 | 2.1% |
| Wave Life Sciences LTD(WVE) | SH | Y95308105 | $118.3M | 18,202,009 | 2.0% |
| Tyra Biosciences Inc(TYRA) | SH | 90240B106 | $116.7M | 12,198,625 | 2.0% |
| GH Research PLC(GHRS) | SH | G3855L106 | $93.6M | 7,676,697 | 1.6% |
| Dyne Therapeutics Inc(DYN) | SH | 26818M108 | $92.5M | 9,714,392 | 1.6% |
| Geron Corp(GERN) | SH | 374163103 | $85.1M | 60,379,366 | 1.4% |
| Disc Medicine Inc(IRON) | SH | 254604101 | $83.5M | 1,577,106 | 1.4% |
| Mineralys Therapeutics Inc(MLYS) | SH | 603170101 | $83.2M | 6,147,280 | 1.4% |
| Septerna Inc(SEPN) | SH | 81734D104 | $73.9M | 6,995,858 | 1.2% |
| Fulcrum Therapeutics Inc(FULC) | SH | 359616109 | $70.4M | 10,229,099 | 1.2% |
| Bicara Therapeutics Inc(BCAX) | SH | 055477103 | $64.6M | 6,955,993 | 1.1% |
| VOR Biopharma Inc | SH | 929033108 | $64.2M | 39,646,039 | 1.1% |
| Taysha Gene Therapies Inc(TSHA) | SH | 877619106 | $54.4M | 23,555,648 | 0.9% |
| Dianthus Therapeutics Inc(DNTH) | SH | 252828108 | $53.4M | 2,866,733 | 0.9% |
| Rxsight Inc(RXST) | SH | 78349D107 | $48.1M | 3,702,967 | 0.8% |
| Tourmaline BIO Inc(TRML) | SH | 89157D105 | $40.6M | 2,538,925 | 0.7% |
| Scholar Rock Holding Corp(SRRK) | SH | 80706P103 | $40.3M | 1,136,453 | 0.7% |
| Climb BIO Inc(CLYM) | SH | 28658R106 | $39.0M | 31,419,267 | 0.7% |
| Structure Therapeutics Inc(GPCR) | SH | 86366E106 | $31.5M | 1,517,418 | 0.5% |
| Solid Biosciences Inc(SLDB) | SH | 83422E204 | $28.3M | 5,811,323 | 0.5% |
| Metsera Inc | SH | 59267L107 | $19.2M | 675,525 | 0.3% |
| Monopar Therapeutics Inc(MNPR) | SH | 61023L207 | $18.3M | 511,207 | 0.3% |
| Nkarta Inc(NKTX) | SH | 65487U108 | $17.9M | 10,805,129 | 0.3% |
| Larimar Therapeutics Inc(LRMR) | SH | 517125100 | $17.5M | 6,045,351 | 0.3% |
| Acumen Pharmaceuticals Inc(ABOS) | SH | 00509G209 | $17.3M | 14,932,063 | 0.3% |
| Enliven Therapeutics Inc(ELVN) | SH | 29337E102 | $17.0M | 848,986 | 0.3% |
| Travere Therapeutics Inc(TVTX) | SH | 89422G107 | $17.0M | 1,150,000 | 0.3% |
| 4D Molecular Therapeutics in(FDMT) | SH | 35104E100 | $16.9M | 4,563,211 | 0.3% |
| Hinge Health Inc(HNGE) | SH | 433313103 | $15.5M | 300,000 | 0.3% |
| Artiva Biotherapeutics Inc(ARTV) | SH | 04317A107 | $14.9M | 9,853,302 | 0.3% |
| Pepgen Inc(PEPG) | SH | 713317105 | $11.9M | 10,689,545 | 0.2% |
| Jade Biosciences Inc(JBIO) | SH | 008064206 | $10.6M | 1,062,326 | 0.2% |
| Tango Therapeutics Inc(TNGX) | SH | 87583X109 | $10.2M | 2,000,000 | 0.2% |
| Acrivon Therapeutics Inc(ACRV) | SH | 004890109 | $9.9M | 8,340,508 | 0.2% |
| Eledon Pharmaceuticals Inc(ELDN) | SH | 28617K101 | $9.7M | 3,566,338 | 0.2% |
| Arcus Biosciences Inc(RCUS) | SH | 03969F109 | $9.3M | 1,136,364 | 0.2% |
| Perceptive Capital Solutions | SH | G70077105 | $8.0M | 750,000 | 0.1% |
| Omada Health Inc(OMDA) | SH | 68170A108 | $7.3M | 400,000 | 0.1% |